<DOC>
	<DOCNO>NCT01752257</DOCNO>
	<brief_summary>The purpose pilot study determine prevalence marker chronic cycle hypoxia reactive specie stress ( oxidative nitrosative ) melanoma tumor microenvironment . The study base around four cornerstone feature pathologic microenvironment - Hypoxia , Reactive Species ( reactive oxygen nitrogen specie ) , HIF-1 VEGF , investigator term HRHV axis . Patients in-transit melanoma ( AJCC Stage IIIB IIIC ) ( 1 ) administer hypoxia marker drug , EF5 , 24 hr prior isolated limb infusion ( ILI ) hyperthermic isolate limb perfusion ( HILP ) . Tumor biopsy perform prior ILI HILP , 30 minute time point ILI ( 60 minute time point HILP ) , AND 24 hour ILI HILP . Tissues obtain snap frozen subsequently analyze EF5 binding . Immunohistochemical analysis cohort immunohistochemical urine marker depict HRHV axis also examine . The association marker presence hypoxia , determine EF5 positivity , determine . Data pilot study use establish prevalence marker HRHV axis melanoma . This information crucial future human trial HRHV axis therapeutically target .</brief_summary>
	<brief_title>EF5 Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>3.1 . Inclusion criterion Histologically confirm AJCC Stage IIIB/IIIC/IV extremity melanoma undergo ILI HILP tumor available biopsy ( NOTE : patient 1 intransit lesion NOT eligible ) Age ≥18 KPS status ≥ 70 Bilirubin ≤ 1.5x normal Creatinine ≤ 1.8 ( EF5 primarily excrete via kidney ) WBC &gt; 3000/mm3 platelet &gt; 100,000/mm3 3.2 . Exclusion criterion Pregnancy breast feeding . A negative serum pregnancy test require woman childbearing potential prior enrollment . Pregnant woman exclude study EF5 agent potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother EF5 , breastfeed discontinue mother give EF5 . Allergy IV contrast dye History grade III IV peripheral neuropathy define NCI CTC ( 2nitroimidazole compound neurotoxic ) Previous history malignancy treat radiotherapy and/or chemohormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Melanoma</keyword>
</DOC>